Clarus Therapeutics Holdings Inc. [CRXT] Is Currently 19.76 above its 200 Period Moving Avg: What Does This Mean?

Related

Clarus Therapeutics Holdings Inc. [NASDAQ: CRXT] stock went on an upward path that rose over 19.76% on Wednesday, amounting to a one-week price increase of more than 30.18%. The company report on May 18, 2022 that Clarus Therapeutics Announces Issuance of Patent Covering JATENZO® (testosterone undecanoate).


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


JATENZO is the first FDA-approved oral softgel for testosterone replacement therapy in adult males who have deficient testosterone due to certain medical conditions .

Clarus plans to list this patent in FDA’s Orange Book, which would bring the total number of Orange Book-listed patents covering JATENZO to eight.

Over the last 12 months, CRXT stock dropped by -95.00%. The one-year Clarus Therapeutics Holdings Inc. stock forecast points to a potential upside of 84.62. The average equity rating for CRXT stock is currently 2.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $23.42 million, with 30.93 million shares outstanding. Compared to the average trading volume of 13.21M shares, CRXT stock reached a trading volume of 14299389 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Clarus Therapeutics Holdings Inc. [CRXT]:

Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for CRXT shares is $3.25 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on CRXT stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.

The Average True Range (ATR) for Clarus Therapeutics Holdings Inc. is set at 0.12, with the Price to Sales ratio for CRXT stock in the period of the last 12 months amounting to 1.67.

CRXT Stock Performance Analysis:

Clarus Therapeutics Holdings Inc. [CRXT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 30.18. With this latest performance, CRXT shares dropped by -8.63% in over the last four-week period, additionally sinking by -91.21% over the last 6 months – not to mention a drop of -95.00% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CRXT stock in for the last two-week period is set at 44.80, with the RSI for the last a single of trading hit 50.36, and the three-weeks RSI is set at 43.77 for Clarus Therapeutics Holdings Inc. [CRXT]. The present Moving Average for the last 50 days of trading for this stock 0.9577, while it was recorded at 0.4198 for the last single week of trading, and 3.2393 for the last 200 days.

Insight into Clarus Therapeutics Holdings Inc. Fundamentals:

Clarus Therapeutics Holdings Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 0.60 and a Current Ratio set at 0.80.

Clarus Therapeutics Holdings Inc. [CRXT] Insider Position Details

There are presently around $1 million, or 33.80% of CRXT stock, in the hands of institutional investors. The top three institutional holders of CRXT stocks are: BRACEBRIDGE CAPITAL, LLC with ownership of 2,002,495, which is approximately 0% of the company’s market cap and around 2.90% of the total institutional ownership; VANGUARD GROUP INC, holding 174,500 shares of the stock with an approximate value of $73000.0 in CRXT stocks shares; and BRIDGEWAY CAPITAL MANAGEMENT, LLC, currently with $38000.0 in CRXT stock with ownership of nearly New of the company’s market capitalization.

10 institutional holders increased their position in Clarus Therapeutics Holdings Inc. [NASDAQ:CRXT] by around 254,917 shares. Additionally, 7 investors decreased positions by around 2,054,410 shares, while 2 investors held positions by with 194,277 shares. The mentioned changes placed institutional holdings at 2,503,604 shares, according to the latest SEC report filing. CRXT stock had 7 new institutional investments in for a total of 226,096 shares, while 6 institutional investors sold positions of 2,045,423 shares during the same period.

[class^="wpforms-"]
[class^="wpforms-"]